Tempus AI FY Conference Summary Company Overview - **Company**: Tempus AI (NasdaqGS:TEM) - **Industry**: Life Sciences, Diagnostics, and Data Analytics Key Points and Arguments Business Model and Strategy - Tempus was founded to leverage AI-enabled diagnostics to unlock precision medicine, focusing on the integration of vast proprietary data and distribution systems to deliver insights to physicians and patients [2][3] - The company has built a substantial dataset of over 400 petabytes, covering phenotypic, morphologic, and molecular data, which is essential for advancing AI in healthcare [5][7] - Tempus connects with over 5,000 providers, reaching two-thirds of the U.S. healthcare system, which allows for extensive data collection and distribution [4][5] Financial Performance - Tempus generated $1.27 billion in revenue for the previous year, exceeding guidance, with a core business growth rate of approximately 30% [33] - The data business alone achieved $316 million in revenue, growing at 31% year-over-year, indicating strong demand from biopharma clients [18][21] - The company expects to generate $1.59 billion in revenue for 2026, with a growth target of 25% over the next three years [33][60] Diagnostic Business - The diagnostic segment includes genomics and genetics, with a focus on therapy selection and monitoring post-treatment [12][13] - The company has seen significant growth in both liquid and solid tumor profiling products, with a 28% growth rate in Q4 [16][39] - Average Selling Prices (ASPs) are expected to rise from $1,630 to approximately $2,200 due to enhanced reimbursement from FDA-approved assays [17][18] Data Business - Tempus has established a robust data business, licensing data to 19 of the 20 largest pharmaceutical companies and over 250 biotech firms [21][44] - The total contract value (TCV) for data licenses is over $1.1 billion, with $350 million related to 2026 being non-cancelable contracts [22][24] - The data business is characterized by high net revenue retention of 126%, indicating strong client loyalty and increasing data licensing [22] AI and Technology Integration - AI is embedded across all Tempus products, enhancing decision-making for physicians and improving patient outcomes [30][31] - The company is developing large multimodal foundation models in partnership with AstraZeneca, leveraging its extensive data for advanced analytics [31][32] Challenges and Future Outlook - Tempus faces challenges in managing rapid growth, particularly in its data business, which is currently experiencing high demand [25][42] - The company is focused on sustainable growth rather than accelerated growth that could lead to volatility in future periods [40][61] - There is ongoing investment in improving product offerings, particularly in the MRD (Minimal Residual Disease) testing segment, to enhance market adoption [56][59] Additional Insights - Tempus has a strong competitive advantage due to its direct data pipeline with hospitals, which is not matched by competitors in the diagnostics space [50][51] - The company has invested over $1 billion in data acquisition and technology, positioning itself as a leader in the market [53][54] This summary encapsulates the key points discussed during the Tempus AI FY Conference, highlighting the company's strategic focus, financial performance, and future growth potential in the life sciences and diagnostics industry.

Company Overview - Tempus aims to unlock precision medicine through AI-enabled diagnostics[6] - The company's platform connects to over 5,000 providers across the US[10] - Tempus leverages a large proprietary healthcare dataset of over 45 million patient records[13] Diagnostics Business - The Diagnostics business delivered approximately 800,000 clinical tests in 2025[30] - The Diagnostics business experienced a unit growth rate of approximately 28% in Q4 2025[30] - Oncology ASP is expected to rise by over $500 in the next several years due to reimbursement tailwinds[31] Data & Applications Business - Data and Applications revenue reached approximately $316 million in 2025, representing approximately 31% growth[38] - The Data & Applications business has signed over $2 billion in contracts to date[38] - The Total Remaining Contract Value (TCV) for Data & Applications is over $1.1 billion as of year-end 2025[39] - The Data Licensing Retention rate is approximately 126% as of year-end 2025[39] Financial Outlook - The company anticipates revenue of approximately $1.27 billion for 2025, reflecting approximately 83% year-over-year growth[63] - The company projects revenue growth of approximately 25% year-over-year in 2026, reaching approximately $1.59 billion[65]

Core Insights - Tempus AI (TEM) stock has achieved a 105% gain over the past year, driven by strong performance in its Genomics and Data segments, exceeding initial expectations for 2025 [1] - The adoption of artificial intelligence (AI) has been a significant catalyst for the company's product portfolio, enhancing the value proposition of its offerings [1] Upsides for TEM Stock - Tempus has received multiple 510(k) clearances from the FDA for its diagnostic and imaging solutions, including the RNA-based Tempus xR IVD device and the updated Tempus Pixel AI-powered cardiac imaging platform [2][3] - The company also secured FDA clearance for its Tempus ECG-Low EF software, which utilizes AI to identify patients with low left ventricular ejection fraction [3] Stable Solvency - Tempus has a well-capitalized balance sheet, ending the last reported quarter with cash and cash equivalents of $760 million and no current debt, providing flexibility amid macroeconomic uncertainty [4] - Long-term debt stood at $1.25 billion, with manageable leverage levels, reflecting a conservative capital structure approach [5] Approach Toward Profitability - The company has shown early signs of profitability, achieving positive adjusted EBITDA of $1.5 million, marking a significant milestone in its financial trajectory [6] - Gross profit nearly doubled year over year in the third quarter, indicating strengthening underlying business economics [7] Price Comparison - Over the past year, TEM stock has outperformed the industry and the S&P 500, as well as competitors like Exact Sciences and GE HealthCare Technologies [9] Average Target Price - Tempus is currently trading 28.6% below its average Zacks price target, indicating strong near-term upside potential [10] Key Challenge for TEM - Despite positive adjusted EBITDA, GAAP losses persist due to stock-based compensation and amortization of acquired intangibles, raising concerns about the quality of profitability [12] - The lack of GAAP net loss guidance limits visibility into the timeline for achieving sustainable GAAP profitability [13] Estimate Revision Trend - Estimates for TEM have narrowed from a loss of 68 cents per share to a loss of 64 cents for 2025 over the past 90 days [15] Strategic Positioning - Tempus' growing portfolio of FDA-cleared diagnostic and AI-driven imaging solutions reinforces its technological leadership and credibility in clinical and life sciences markets [16] - The company is well-positioned to continue investing in AI innovation and data infrastructure, although GAAP losses and limited visibility into sustainable profitability remain key considerations [16]

Core Viewpoint - Tempus AI stock is currently in a bear market, having experienced a significant decline of 36% from its peak in September of the previous year [1] Group 1: Stock Performance - The stock price has fallen to $66, indicating a substantial drop from its previous highs [1] - The market capitalization of Tempus AI has decreased from $17.8 billion in October [1]

Core Insights - Tempus AI reported preliminary unaudited financial results for the fourth quarter and full year ending December 31, 2025, with total revenue of approximately $1.27 billion, representing a year-over-year growth of about 83% [1] - The company's diagnostic business revenue reached approximately $955 million, a year-over-year increase of about 111%, driven by a 26% increase in tumor testing volume and a 29% increase in genetic testing volume [1] - The data and applications segment generated revenue of $316 million, reflecting a year-over-year growth of about 31%, primarily due to a 38% increase in Insights business [1] Revenue Breakdown - For Q4 2025, Tempus AI reported revenue of approximately $367 million, a year-over-year increase of about 83% [1] - Diagnostic business revenue for Q4 was approximately $266 million, showing a year-over-year growth of about 121%, driven by a 29% increase in tumor testing volume and a 23% increase in genetic testing volume [1] - Data and applications revenue for Q4 was approximately $100 million, with a year-over-year growth of about 25%, and Insights business growth of approximately 68% when excluding the impact of AstraZeneca warrants from Q4 2024 [1] Strategic Outlook - CEO Eric Lefkofsky highlighted that 2025 was an exceptional year for Tempus, with both product lines exceeding initial expectations [2] - The genomic (tumor) product testing volume has accelerated for three consecutive quarters, achieving the highest unit growth rate in years [2] - The company anticipates a strong entry into 2026, with accelerating growth in both main business segments and the inherent financial leverage of its platform being released [2]

Financial Results - Tempus AI, Inc. reported preliminary financial results for Q4 and full year 2025 on January 11, 2026[6] - The total remaining contract value as of December 31, 2025, was disclosed in a press release on January 11, 2026[8] Corporate Communication - The company made an updated corporate presentation available on its investor relations website on January 11, 2026[9]

Market Overview - U.S. stock futures declined on Monday following a positive close on Friday, with major benchmark indices trading lower [1] - The Dow Jones, S&P 500, and Nasdaq 100 experienced declines of 0.78%, 0.76%, and 1.04% respectively in premarket trading [4] Economic Indicators - Nonfarm payrolls increased by 50,000 in December, slightly below expectations of 60,000 and down from November's revised gain of 56,000 [2] - The 10-year Treasury bond yielded 4.19%, while the two-year bond was at 3.53%, with a 95% likelihood of the Federal Reserve keeping interest rates unchanged in January [3] Company Performance - Vistra Corp. (NYSE:VST) rose 0.69% after signing a 20-year nuclear power deal with Meta Platforms Inc. (NASDAQ:META) [7] - Alibaba Group Holding Ltd. (NYSE:BABA) increased by 4.44% as its Cloud's Qwen series became the most widely used open-source AI system, surpassing 700 million downloads [7] - Tempus AI Inc. (NASDAQ:TEM) jumped 8.12% after reporting a record $1.1 billion in total contract value and approximately 126% net revenue retention for 2025 [7] - Xpeng Inc. (NYSE:XPEV) gained 2.75% after unveiling its global 2026 P7+ flagship and reporting 126% delivery growth in 2025 [14] - Boot Barn Holdings Inc. (NYSE:BOOT) saw a slight decline of 0.37% despite reporting preliminary third-quarter net sales of $705.6 million, a 16.0% increase over the prior year [14] Sector Performance - Materials, utilities, and consumer discretionary stocks posted the largest gains on Friday, while health care and financial shares closed lower [9] - For the week, the S&P 500 rose 1%, with the Dow and Nasdaq increasing by 2.3% and 1.9% respectively [9] Upcoming Economic Data - Key economic data releases include December's NFIB optimism index, CPI data, and U.S. budget deficit, with several Federal Reserve officials scheduled to speak throughout the week [13][16]

Core Insights - Tempus AI, Inc. has achieved a record Total Contract Value (TCV) exceeding $1.1 billion as of December 31, 2025 [1] - The company signed data agreements with over 70 customers in 2025, including major pharmaceutical companies [1] Company Overview - Tempus AI, Inc. is a technology company focused on advancing precision medicine through the adoption of artificial intelligence [1] - The company operates in the healthcare technology sector, specifically targeting the pharmaceutical industry [1] Customer Engagement - The customer base includes both large and mid-sized pharmaceutical companies such as AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, and Boehringer Ingelheim [1] - The agreements signed in 2025 reflect a strong demand for Tempus's AI-driven solutions in the pharmaceutical sector [1]

"2025 was an exceptional year for Tempus with the strength of both of our product lines exceeding our initial expectations for the year,†said Eric Lefkofsky, Founder and CEO of Tempus. "Within Diagnostics, year- over-year volume growth of our genomics (oncology) offering accelerated for the third consecutive quarter hitting the highest unit growth rate we have seen in years. Our Data and Application business is performing even better with record revenue of ~$100 million in the fourth quarter, achieving full ...

Core Insights - Tempus AI (TEM) has experienced significant growth, with shares increasing by 82.4% over the past year, outperforming the industry growth of 2.6% and the S&P 500's 19.3% increase [1][10] Company Performance - Tempus has achieved profitability on a non-GAAP basis and is focusing on disciplined expansion and long-term growth, with a portfolio that includes oncology therapy selection, hereditary testing, and minimal residual disease (MRD) [2] - The company reported a positive adjusted EBITDA of $1.5 million in the third quarter, marking a significant milestone after a decade of efforts [7] Revenue Segments - The Genomics segment has seen revenues more than double year-over-year, driven by increased oncology testing volumes and the integration of Ambry hereditary testing, with total genomics testing volumes rising by 33% [4][10] - The Data & Services segment has emerged as a high-margin revenue stream, with revenues growing by 26.1% year-over-year, primarily due to data licensing [6] Regulatory Developments - In September 2025, Tempus received FDA 510(k) clearance for its xR IVD to support drug development programs and launched a new liquid biopsy assay for treatment response monitoring [5] Market Outlook - The Zacks Consensus Estimate projects a 59.5% improvement in loss per share for 2025 and a 71.6% improvement for 2026, with revenues expected to grow by 82.3% to $1.26 billion in 2025 and reach $1.56 billion in 2026 [11]